Opinion
Video
Specialists’ Individual Treatment Plans for Patients With FCS: Pancreatic Specialist
Author(s):
Key Takeaways
- Delayed FCS diagnosis can lead to exacerbated cardiovascular and metabolic consequences, increasing atherosclerosis and cardiovascular disease risk.
- Persistent hypertriglyceridemia from untreated FCS may result in chronic pancreatitis, diabetes, and liver disease.
Panelists discuss their specific areas of focus in the care for a patient with familial chylomicronemia syndrome (FCS) as endocrinologists, cardiologists, internists, and pancreatic specialists, outlining primary treatment goals, such as reducing triglyceride levels below 500 mg/dL to lower the risk of acute pancreatitis, and providing recommendations to support optimal collaboration across all specialties involved in managing FCS.
Video content above is prompted by the following:
What are your specific areas of focus in FCS patient care as a [endocrinologist / cardiologist / internist / pancreatic specialist]when treating a patient with FCS?
What are your primary treatment goals?
Reference NLA/NCEP III/AHA clinical guidelines regarding triglyceride levels of less than 500 to reduce the risk of acute pancreatitis.
What are your recommendations to support optimal collaboration across all specialties involved with managing FCS?
